Chronic administration of LJ-2698 (a novel orally-active and highly selective A3AR antagonist) to these animals was more efficient in preventing diabetic nephropathy progression than the widely used AT1 receptor antagonist, losartan (Table 2) (Dorotea et al., 2018). Here, ADORA3 is linked to diabetic kidney disease.